



MEDICAL TIPS

BLUGLIP Tablets

Issue I, No. 2, 2023

Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study.

Vangaveti VN et al. Diabetology & Metabolic Syndrome 2022; 14.

- Diabetic foot ulcers (DFU) are one of the leading long-term complications in patients with diabetes, for which DPP4 inhibitors may have a beneficial effect on the healing.
- In a randomized, double-blind, placebo-controlled study, 50 participants with foot ulcer grade A1 or higher were equally divided into the placebo group or treated with vildagliptin and monitored for the DFU sizes and inflammatory markers for 12 weeks.
- Apart from the reduction in HbA1c, hematocrit, total cholesterol, LDL cholesterol, vildagliptin treatment showed a protective effect on DFU wound healing by 35% compared to the placebo.
- The C reactive protein, WBC and neutrophils were also reduced in the vildagliptin group as compared to the placebo group.

Vildagliptin treatment was effective in healing DFU in addition to controlling the diabetes and findings support the use of DPP4is as a preferred option for treating ulcers in patients with diabetes.

